The infection of the Sars-coV-2 virus (Covid-19) is now regarded as a pandemic. However, a globally inclusive examination concerning this infection is not accounted for. As a result, this study attempted to investigate the disease's risk factors to improve control and prevention. The illness risk variables were assessed in this case-control study, which included 721 patients diagnosed with COVID-19 and 2083 people in the control group. Logistic regression was used to assess all of the data statistically. COVID-19 was linked to cardiovascular disease (P = 0, OR = 4.9), hypertension (P = 0, OR = 6.4), diabetes (P = 0, OR = 7.1), occupational health and treatment (P = 0, OR = 92), and contact with COVID-19 patients (P = 0, OR = 438), according to the results of logistic regression. Underlying illnesses linked to Covid-19, such as hypertension, a history of cardiac disease, diabetes, occupational health, and direct contact with a Covid-19 patient, were found to have a link to our findings in this study.
1. (2019-nCoV). JTM. 2020. doi:10.1093/jtm/taaa015.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. doi:10.1056/NEJMoa2001017.
3. Ghebreyesus TA. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020; 2020.
4. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-23. doi:10.1016/S0140-6736(20)30154-9.
5. John Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020. Available from: https://coronavirus.jhu.edu/map.html. Accessed 14 Apr 2020.
6. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-4. doi:10.1016/S1473-3099(20)30120-1.
7. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveill. 2020;25(3):2000045. doi:10.2807/1560-7917.ES.2020.25.3.2000045.
8. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020. doi:10.1016/j.jpha.2020.03.001
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.
10. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020;20(7):776-7. doi:10.1016/S1473-3099(20)30244-9.
11. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669-77. doi:10.1016/S1473-3099(20)30243-7.
12. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020. doi:10.1056/NEJMoa2002032.
13. China CDC Weekly. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. Available from: http://weekly.chinacdc.cn/fileCCDCW/journal/article/ccdcw/2020/8/PDF/COVID-19.pdf (accessed on May 8, 2020).
14. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020. doi:10.1056/NEJMc2010419
15. Knapp S. Diabetes and infection: Is there a link?-A mini-review. Gerontology. 2013;59(2):99-104.
16. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906-12.
17. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-8.
18. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020:2000547. doi:10.1183/13993003.00547-2020.
19. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PloS one. 2020;15(5):e0233147.
20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
21. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;368(2):641-3.
22. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95(9):634-5.
23. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7.
24. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 28, 2020. Available from: https://www.who.int/docs/ default-source/coronaviruse/clinicalmanagement-of-novel-cov.pdf? sfvrsn¼bc7da517_6&download¼true.
25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Copyright © 2023 - All Rights Reserved - Archives of Pharmacy Practice
Developed by Archives of Pharmacy Practice